Saturday 17 October 2026
Export RNTX’s income statement to Excel — free account
Rein Therapeutics Inc.
RNTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 64.3% and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.59
0.04
−6.35%
Follow RNTX
Rein Therapeutics Inc. (RNTX) P/E ratio
Rein Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GUTS Fractyl Health, Inc. compare | n/m |
| BOLD Boundless Bio, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. | n/m |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | n/m |
| GOSS Gossamer Bio, Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| RNXT RenovoRx, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)